Viridian locks in WuXi Biologics for 5-year veligrotug manufacturing deal

Filed May 26, 2026 · Period ending May 24, 2026 · ~1 min read

Key Changes

• high

  Viridian secured WuXi Biologics as commercial manufacturer for veligrotug drug supply if approved, positioning the company for potential product launch while maintaining flexibility through non-exclusive arrangement.

  Item 1.01 verify on EDGAR →
• medium

  Agreement includes binding volume commitments based on monthly forecasts, with fixed pricing through December 2026 then annual volume-based adjustments—creating financial obligations regardless of commercial success.

  Item 1.01 verify on EDGAR →
• medium

  Five-year term auto-renews unless either party gives 24 months' notice, limiting exit flexibility but providing long-term supply stability for approved product.

  Item 1.01 verify on EDGAR →